Mammograms May Benefit Women Well Into Their 80s, UCLA Study Finds

For many older women, the question of whether to continue breast cancer screening has been uncertain. While most guidelines recommend mammograms up to age 74, advice for women 75 and older has been less clear. Now, a new study from researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests that regular mammograms may still offer significant benefits for women in their 80s.

The study, published in the Annals of Surgical Oncology, found that women in their 80s who get regular mammograms are more likely to have breast cancer detected early, need less aggressive treatment and live longer.

“When cancer is found on screening, it is often early stage,” said Dr. Nimmi Kapoor, an associate professor of surgery at the David Geffen School of Medicine at UCLA and senior author of the study. “In postmenopausal women with the most common hormone-sensitive breast cancers, we can often omit sentinel lymph node biopsy, chemotherapy, and sometimes even radiation. Screening is especially important in this era of de-escalation because early detection allows us to safely reduce the intensity of treatment while still achieving excellent outcomes.”

The number of older adults in the U.S. has grown rapidly over the past decade, and age is a major risk factor for breast cancer. As a result, determining the most effective way to screen older women has become increasingly important, the researchers noted. Yet guidance is limited, leaving many women and their doctors uncertain about when to continue or stop routine mammograms. Screening in older women also raises concerns about overdiagnosis, when cancers are detected that may never cause problems, and the associated costs.

With limited data on the benefits of mammography for women over 80, the researchers set out to compare outcomes between those who continued regular screening and those who did not.

The team analyzed medical records of 174 women aged 80 and older who were diagnosed with breast cancer at UCLA between 2013 and 2020. Most cancers were estrogen receptor–positive and HER2-negative and were mostly stage 1 or 2. Patients were divided into two groups: Those who had a mammogram within two years before their diagnosis (98 women) and those who did not (76 women). They then compared outcomes —including cancer stage at diagnosis, treatment intensity, and overall survival— between the two groups.

They found that women who did not have regular mammograms were more likely to have tumors that were advanced, high-grade or noticeable by touch. Screened women were more likely to have surgery to remove the tumor, while unscreened women sometimes omitted surgery altogether.

After a median follow-up of 55 months, they found women who were screened had a 55% lower risk of their cancer returning and a 74% lower risk of dying compared with women who were not screened. These advantages remained even after accounting for age, tumor type, and whether they had surgery.

“We were surprised to see such a significant survival difference among these women in their 80s,” said Kapoor, who is also an investigator in the UCLA Health Jonsson Comprehensive Cancer Center. “Our findings underscore the importance of encouraging breast cancer screening in elderly patients, regardless of age, unless they have more pressing health issues. Current guidelines are vague and often left to the provider’s discretion, so studies like ours help provide much-needed data for this underrepresented population.”

While the findings are encouraging, the researchers noted some limitations. The study looked back at medical records and only included women who were ultimately diagnosed with breast cancer, so it doesn’t capture potential downsides of screening, such as false positives, extra tests, or the emotional and financial stress on patients and their families. Larger studies are needed to confirm the benefits of mammograms for older women and to guide clearer screening recommendations.

Reference:

Siu‑Yuan Huang, Impact of Screening Mammography on Breast Cancer Outcomesin Women Aged 80 Years and Over, Annals of Surgical Oncology, https://doi.org/10.1245/s10434-025-18288-4

Powered by WPeMatico

Constipation May Increase Risk of Death in CKD and Heart Failure: Meta-Analysis Reveals

China: A new meta-analysis published in Annals of Medicine suggests that constipation may be associated with an increased risk of all-cause mortality, particularly among individuals with chronic health conditions such as chronic kidney disease (CKD) and heart failure. Interestingly, no clear link was observed between constipation and cardiovascular-specific mortality, highlighting the need for further research to clarify its prognostic role.                  

The study was conducted by Dr. Bing Liu and colleagues from the Department of Anorectal Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China. The researchers systematically reviewed longitudinal observational studies examining the relationship between constipation and mortality outcomes. A total of 13 studies, reported across 14 articles and including over 3.7 million participants, were analyzed to determine pooled hazard ratios (HRs) for all-cause and cardiovascular mortality.
Key Findings:
  • Constipation was associated with a 10% increased risk of all-cause mortality in the general population.
  • In patients with chronic kidney disease, constipation was linked to a 40% higher risk of all-cause mortality (HR 1.40).
  • Individuals with heart failure had an 85% higher risk of all-cause mortality associated with constipation (HR 1.85).
  • No significant association was observed between constipation and cardiovascular mortality in the general population (HR 1.19).
  • Constipation was not significantly linked to cardiovascular mortality among CKD patients (HR 1.33).
  • The findings suggest that increased all-cause mortality may be driven by factors related to chronic disease rather than direct cardiovascular effects.
The study’s findings highlight the importance of recognizing constipation as a potential marker for poorer outcomes in patients with chronic illnesses. The authors suggest that routine assessment of bowel health could provide additional insight into overall patient risk and may help identify individuals who might benefit from more intensive monitoring or intervention.
However, the authors caution that the results should be interpreted in light of several limitations. The included studies were observational, limiting the ability to establish causality. Definitions and assessments of constipation varied across studies, which could influence the pooled risk estimates. Residual confounding factors such as diet, physical activity, and medication use may also have affected the results. Additionally, most CKD participants were dialysis patients, which may not reflect the broader CKD population, and language restrictions could have excluded relevant research published in non-English sources.
Despite these limitations, the meta-analysis provides compelling evidence that constipation is independently associated with increased all-cause mortality, especially in chronic disease populations. The researchers recommend standardizing constipation assessment and validating these findings across diverse cohorts to better understand its prognostic significance.
“While constipation does not appear to significantly impact cardiovascular-specific mortality, it may serve as an important indicator of overall health risk, particularly in patients with chronic kidney disease or heart failure. Further studies are needed to explore underlying mechanisms and to determine whether targeted interventions for constipation could improve long-term outcomes in these vulnerable populations,” the authors concluded.
Reference:
Liu, B., Wu, X., Wang, Y., & Hu, X. (2025). Association between constipation and risk of cardiovascular or all-cause mortality: a meta-analysis. Annals of Medicine, 57(1). https://doi.org/10.1080/07853890.2025.2561803

Powered by WPeMatico

High protein or Trp diet increases risk of cancer-associated VTE: Study

Next to cancer recurrence or progression, cardiovascular diseases are the leading causes of death in cancer survivors. The Surveillance, Epidemiology, and End Results database revealed that among the more than three million who initially survived cancer between 1973 and 2012, 38% eventually succumbed to the disease while 11.3% died from cardiovascular diseases. Specifically, cancer survivors are at a four to seven-fold higher risk of venous thromboembolism (VTE), which proves fatal in one out of seven cancer patients.

While the effects of high-fat diets have been studied in the context of cancer and cardiovascular disease, sparse information is available on the impact of a high-protein diet and cancer-associated thrombosis.

In a new study from Boston University Chobanian & Avedisian School of Medicine, researchers have found that a high protein diet, or a diet high in amino acid tryptophan (Trp). Trp is abundant in various protein-rich foods increases the risk of cancer-associated VTE in experimental models.

“Although our new findings are based on experimental models, we believe that knowledge gained from this study could prompt interest in further testing relevance to the human condition,” says co-corresponding author Katya Ravid, the Barbara E. Corkey professor at the school.

The researchers found that experimental models with colon cancer who were fed a high protein diet or a diet rich with Trp experienced more severe development of vascular thrombosis compared to the groups that had been fed a regular balanced diet. They also found that inhibiting the key enzyme responsible for the metabolism of tryptophan reduced the severity of vascular injury. Finally, they found that Kynurenine, a known metabolite of tryptophan, has an effect on blood coagulation factors that are known to promote thrombosis.

According to the researchers, this work has potential implications at the individual patient and population levels. “Nutrition management is an integral component of cancer patient care. Patients with cancer are often advised to increase their dietary protein intake to compensate for cancer-cachexia (involuntary weight loss, muscle wasting, and loss of appetite, leading to significant weakness and fatigue) and chemotherapy side-effects. At times, these patients receive parenteral nutrition (feeding directly into the bloodstream), including approximately five to eight times more Trp than dietary recommendation,” explains co-corresponding author Vipul Chitalia, MD, PhD, professor of medicine. 

Reference:

Lotfollahzadeh S, Jose A Dr, Yang X, Bathla T, Lazowski A, Hoekstra I, Sethuraman K, Potluri S, Dulberger K, La J, Fillmore N, Piqueras MDC, Lee N, Cabral HJ, Ravid K, Chitalia V. Dietary Tryptophan Augments Cancer-Associated Venous Thrombosis Mitigated by Indoleamine 2,3-Dioxygenase 1 Inhibition. Blood Adv. 2025 Jul 16:bloodadvances.2025017079. doi: 10.1182/bloodadvances.2025017079. 

Powered by WPeMatico

Tylenol, autism and the difference between finding a link and finding a cause in scientific research

Claims from the Trump White House about links between use of the painkiller acetaminophen—often sold under the brand name Tylenol in the U.S.—during pregnancy and development of autism have set off a deluge of responses across the medical, scientific and public health communities.

Powered by WPeMatico

Tylenol, autism and the difference between finding a link and finding a cause in scientific research

Claims from the Trump White House about links between use of the painkiller acetaminophen—often sold under the brand name Tylenol in the U.S.—during pregnancy and development of autism have set off a deluge of responses across the medical, scientific and public health communities.

Powered by WPeMatico

Taller, leaner, faster: The evolution of the ‘perfect’ AFL body

Geelong champion Patrick Dangerfield wowed the AFL world during last week’s preliminary final win against Hawthorn, pushing his 35-year-old body to the limit to propel his team into this year’s Grand Final.

Powered by WPeMatico

Taller, leaner, faster: The evolution of the ‘perfect’ AFL body

Geelong champion Patrick Dangerfield wowed the AFL world during last week’s preliminary final win against Hawthorn, pushing his 35-year-old body to the limit to propel his team into this year’s Grand Final.

Powered by WPeMatico

Mediterranean-style diets may still lower cardiovascular risk independent of lean beef intake

National Cattlemen’s Beef Association funded research finds that Mediterranean-style eating with lean beef produces less trimethylamine N-oxide (TMAO) compared with a typical American diet that included the same amount of beef.

Powered by WPeMatico

Himachal Drug Makers Unfazed by US 100% Tariff on Branded Drugs

Shimla: Pharmaceutical manufacturers in Himachal Pradesh have said the U.S. decision to impose 100% tariffs on branded and patented medicines is unlikely to cause major disruptions, as the state’s pharma sector is overwhelmingly focused on generics.

The new duty, set to take effect from October 1, will apply to imported branded and patented drugs. However, industry leaders in Himachal, home to a large concentration of pharma companies, stressed that the state’s drug makers are shielded from the impact.

“More than 95 per cent of pharmaceutical companies located in Baddi, Nalagarh, Kala Amb and Paonta Sahib are engaged in producing generic medicines,” expressed Sanjay Suri, Vice-Chairman of CII Himachal and Executive Director of Morepen Laboratories. He added that India’s role as one of the largest exporters of generics to the U.S. makes it difficult for American healthcare to risk imposing tariffs on this segment, as it would directly increase treatment costs for patients.

While industry leaders appeared confident, some struck a note of caution. Rajesh Gupta, Chairman of the Himachal Drug Manufacturers’ Association, said the exemption for generics must be clearly defined. “The distinction between generic and branded or patented drugs is not always straightforward,” he noted, adding that some companies manufacture branded medicines outside the state. According to him, clarity in the tariff notification is essential to prevent confusion.

Himachal Pradesh is among India’s leading pharma hubs, with around 580 pharmaceutical units operating in the state. Nearly 79 per cent of them are based in the Baddi-Nalagarh-Barotiwala belt of Solan district, while the remaining are concentrated in Kala Amb and Paonta Sahib in Sirmaur. Together, the state’s pharmaceutical industry boasts an estimated annual turnover of ₹40,000 crore, contributing significantly to India’s drug exports.

According to a recent media report in The Indian Express, the general consensus among industry players is that Himachal’s pharma sector will remain largely unaffected, unless the U.S. extends tariffs to generic medicines in the future.

Powered by WPeMatico

PCI Bars 89 Pharmacy Colleges in Maharashtra from 2025-26 Admissions Over Regulatory Lapses

Mumbai: In a major crackdown on regulatory lapses, the Pharmacy Council of India (PCI) has prohibited 89 pharmacy colleges across Maharashtra, including 71 diploma and 18 degree institutions, from admitting students for the 2025-26 academic session.

According to a recent media report in the Times of India, the move follows three years of inspections by PCI and state technical education bodies, which exposed serious violations ranging from absence of fire and safety certificates and missing occupancy approvals to poorly equipped laboratories, infrastructure deficiencies, and unqualified faculty members. In several cases, colleges attempted to submit certificates issued by unrecognized local bodies or private agencies, which were dismissed as invalid by inspectors.

After issuing showcause notices and conducting follow-up inspections, the PCI released a circular formally declaring these colleges “Not to make admission” for the upcoming academic year. The affected institutes are spread across districts including Thane, Kolhapur, Nagpur, Nashik, and Solapur.

The council underlined that the action was essential to protect students and uphold minimum academic standards in pharmacy education. Officials noted that despite repeated warnings, many institutions failed to rectify their shortcomings.

Times of India reports that this sweeping decision is also expected to delay the state’s overall pharmacy admission process, as authorities will need to recast the seat matrix and students will be left to pick from revised options.

Powered by WPeMatico